Wave makes $100M pub­lic of­fer­ing af­ter dos­ing first sub­jects with GSK-part­nered RNA edit­ing drug

Wave Life Sci­ences is of­fer­ing $100 mil­lion in shares just short­ly af­ter it start­ed test­ing its first RNA edit­ing can­di­date in healthy sub­jects, which trig­gered a pay­out from Big Phar­ma part­ner GSK.

The biotech an­nounced the pub­lic of­fer­ing on Wednes­day, the same day it be­gan dos­ing healthy vol­un­teers with its al­pha-1 an­tit­rypsin de­fi­cien­cy (AATD) treat­ment can­di­date, WVE-006. Wave’s RestorAA­Tion pro­gram com­pris­es two tri­als — RestorAA­Tion-1 is fo­cused on healthy sub­jects, and RestorAA­Tion-2 is en­rolling AATD pa­tients with a ho­mozy­gous PiZZ mu­ta­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER